{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-005504","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.764616+00:00","generated_at":"2026-06-16T05:55:02.249656+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Palatin to host KOL webinar on PL9643 Phase 3 dry eye data on May 8, 2023","bullets":["Webinar to review positive PL9643 Phase 3 MELODY-1 Lead-In population data for moderate to severe dry eye disease.","Final PL9643 Phase 3 MELODY-1 data expected in H2 2023; trial enrollment continuing.","Webinar moderated by CEO Carl Spana; featuring KOLs Dr. Stouch, Mr. Ousler, and CMO Dr. Raizman.","Company cites PL9643 positive effects on both signs and symptoms of dry eye disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-005504","json":"https://secwatch.observer/filing/0001654954-23-005504.json","markdown":"https://secwatch.observer/filing/0001654954-23-005504.md","text":"https://secwatch.observer/filing/0001654954-23-005504.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495423005504/0001654954-23-005504-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495423005504/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T05:55:02.249656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}